Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · PAVmed Inc. (PAVM)

PAVmed narrows Q2 2026 net loss to $5.5 million from $13.3 million a year earlier

Positive Impact 3 of 5 earnings Written later

PAVmed reported results for the quarter ended June 30, 2026, with a GAAP net loss attributable to common stockholders of $5.5 million, or $(0.87) per diluted share, compared with a loss of $13.3 million, or $(22.08) per share, a year earlier. The company also gave a business update on subsidiaries Lucid Diagnostics and Veris Health, including a first laboratory benefit manager coverage policy for EsoGuard.

Key points

  • GAAP net loss attributable to common stockholders was $5.5 million, or $(0.87) per diluted share, for the three months ended June 30, 2026, versus $13.3 million, or $(22.08) per share, a year earlier.
  • Non-GAAP adjusted loss was $1.7 million, or $(0.27) per share, for the quarter; cash and cash equivalents were $3.8 million as of June 30, 2026, up from $1.5 million at December 31, 2025.
  • Lucid Diagnostics recognized $1.5 million in EsoGuard revenue for the second quarter and processed 2,770 EsoGuard tests.
  • Veris Health is targeting an early 2027 FDA 510(k) submission for its implantable physiological monitor.

The filing

CompanyPAVmed Inc. (PAVM)
Form8-K, current report
Filed with the SECAug 14, 2026, 10:44 AM ET
Accession number0001493152-26-038072

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.